Precision Optics (POCI) ended fiscal 2026 with a quarter that looks like the inflection management had been promising. It then guided investors to a year that largely pauses that story. The company lost $0.01 per share on record revenue of $8.77 million for the June quarter. Earnings improved 94.4% year over year from a $(0.18) loss, and revenue grew 42.0%. Adjusted EBITDA was positive for a second straight quarter at $355,000. Fiscal 2026 revenue of $31.5 million beat the $29 to $31 million range management had already raised on the prior call. That is the central tension. The fourth quarter showed what the business can earn with its largest satellite program running at full speed. The fiscal 2027 outlook, however, shows how dependent the model still is on that single customer.
The quality of the quarter deserves scrutiny on three fronts. First, the top line has stalled on a sequential basis. Revenue was essentially unchanged from the $8.7 million reported in the March quarter, and 42% year-over-year growth is a clear step down from the 65% full-year pace. Second, the gross margin of 25.3%, up from 23.6% in the prior quarter and 13.0% a year ago, includes about 3 points of benefit from IEEPA tariff refunds. Those refunds lowered cost of goods sold by roughly $707,000 and reduced revenue by about $558,000, and they will not recur. Third, the per-share improvement came against a much larger share base. Weighted shares rose to 10.9 million from 7.7 million after a $10.6 million public offering. Operating improvement was real: the operating loss narrowed to about $107,000 from $1.36 million a year ago. But the clean-looking margin and EPS figures overstate the run rate.
The call explained why management is not extrapolating the quarter. The existing satellite customer's slowdown is now considerably worse than described in May. That call flagged a 15% to 20% pullback with reorders in the third fiscal quarter. Management now expects roughly a 40% revenue reduction in the September quarter, a further cut in December, and recovery around the end of fiscal 2027. The mix makes this worse, because the satellite program carries higher margins than the revenue meant to replace it. Management also conceded that the engineering pipeline became too concentrated. Engineering revenue fell to about $0.8 million in the fourth quarter from $1.1 million in the third, and to $3.5 million for the year from $4.9 million. The prior call's talk of five or six programs moving into production in fiscal 2027 received little quantification this time.
The fiscal 2027 guidance resets the story. Management expects revenue of $30 million to $33 million, roughly flat after 65% growth. It guided adjusted EBITDA to a loss of $1.2 million to $1.7 million, with quarterly losses returning early in the year. The annual EBITDA figure is technically an improvement on fiscal 2026's $(2.1) million loss. But it is a clear retreat from the prior call's framing of near-breakeven and growing profitability. The guidance is also back-half weighted and rests on satellite orders resuming, which leaves it exposed to further timing slippage.
The offsets are credible, if early. Production execution is strong:
- Satellite line yields reached a record 99%, and the ophthalmic line is at 94% under the $3.5 million follow-on order.
- Two cystoscopy lines are running multiple shifts, and management expects a follow-on order without interruption.
- Ross Optical grew 55% to about $1.5 million.
- A $1.3 million defense follow-on accompanied a multi-year program renewal, and the parties are working on a continuous-production agreement.
The most interesting new development is a second satellite-constellation customer. It placed two engineering orders of about $50,000 each and is targeting production within six to 12 months. Management said the opportunity could exceed the existing $13 million-plus program, with more content per unit. That is a genuine catalyst, but it is still at the engineering-order stage and could not affect results before late fiscal 2027.
The balance sheet provides runway, though not unlimited. Cash was $9.8 million, up from $1.8 million a year ago thanks to the offering. It fell from $10.7 million during the quarter, and management said no equity raise is planned barring an unusual event. Market context is thin. Shares opened at $5.00 after the May report, above a 200-day moving average now at $4.60. Investors will likely be forced to reassess whatever premium the inflection narrative earned.
The bottom line is that Precision Optics delivered the operating proof points it promised in fiscal 2026: record revenue, positive adjusted EBITDA, improving yields and a stronger balance sheet. However, the guidance shows the growth engine is on hold until its dominant satellite customer returns. Bears have legitimate ammunition in customer concentration, a thinning engineering pipeline and a tariff-aided margin. Bulls have a credible case built on production execution and a potentially larger second satellite relationship. Fiscal 2027 will test whether diversification can arrive before the existing program recovers.